Norges Bank Makes New $1.54 Million Investment in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Norges Bank bought a new position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 482,200 shares of the company's stock, valued at approximately $1,543,000. Norges Bank owned 0.38% of Organogenesis at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in shares of Organogenesis by 36.4% during the 4th quarter. JPMorgan Chase & Co. now owns 280,997 shares of the company's stock worth $899,000 after acquiring an additional 75,054 shares during the period. Prudential Financial Inc. boosted its holdings in shares of Organogenesis by 92.9% in the 4th quarter. Prudential Financial Inc. now owns 237,720 shares of the company's stock valued at $761,000 after purchasing an additional 114,500 shares during the last quarter. American Century Companies Inc. boosted its holdings in Organogenesis by 10.4% in the fourth quarter. American Century Companies Inc. now owns 98,892 shares of the company's stock valued at $316,000 after acquiring an additional 9,311 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Organogenesis in the 4th quarter worth about $38,000. Finally, Cornerstone Investment Partners LLC purchased a new stake in shares of Organogenesis during the 4th quarter worth about $162,000. 49.57% of the stock is owned by institutional investors and hedge funds.

Organogenesis Stock Down 0.2 %

Shares of ORGO traded down $0.01 during midday trading on Tuesday, reaching $4.32. 1,343,991 shares of the company were exchanged, compared to its average volume of 1,116,915. Organogenesis Holdings Inc. has a 1-year low of $2.17 and a 1-year high of $6.71. The stock has a 50-day moving average price of $4.34 and a 200-day moving average price of $3.70. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The company has a market cap of $547.90 million, a price-to-earnings ratio of -72.00 and a beta of 1.79.

Remove Ads

Analyst Upgrades and Downgrades

Separately, Morgan Stanley lifted their price target on shares of Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a research report on Wednesday, March 5th.

Insider Buying and Selling

In related news, Director Michael Joseph Driscoll sold 25,000 shares of Organogenesis stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the sale, the director now owns 166,879 shares of the company's stock, valued at $851,082.90. The trade was a 13.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 36.90% of the stock is currently owned by corporate insiders.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.